Stockscreener 앱 받기
426.39
0.07%
0.3868
전일 마감가:
$426.00
열려 있는:
$418.55
하루 거래량:
1.28M
Relative Volume:
0.71
시가총액:
$109.30B
수익:
$11.39B
순이익/손실:
$3.64B
주가수익비율:
30.48
EPS:
13.9904
순현금흐름:
$3.50B
1주 성능:
+0.93%
1개월 성능:
+5.70%
6개월 성능:
-14.94%
1년 성능:
-9.84%
1일 변동 폭
$403.16
$430.71
1주일 범위
$403.16
$430.71
52주 변동 폭
$362.50
$519.88
버텍스 파마슈티컬 Stock (VRTX) Company Profile
명칭
Vertex Pharmaceuticals Inc
전화
(617) 341-6393
주소
50 NORTHERN AVENUE, BOSTON, MA
VRTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
426.30 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
631.36 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.19 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
836.24 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.55 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
버텍스 파마슈티컬 Stock (VRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-25 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 개시 | Raymond James | Mkt Perform |
| 2025-08-06 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | 업그레이드 | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2024-12-19 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Perform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 개시 | Redburn Atlantic | Buy |
| 2024-04-11 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-02-06 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-02 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | 다운그레이드 | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 재확인 | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 개시 | William Blair | Outperform |
| 2023-05-04 | 재개 | Piper Sandler | Overweight |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Hold |
| 2023-01-17 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-06-01 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-05-06 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 재확인 | JP Morgan | Overweight |
| 2022-01-27 | 재확인 | Morgan Stanley | Underweight |
| 2022-01-27 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-01-27 | 재확인 | Stifel | Hold |
| 2022-01-27 | 재확인 | Wolfe Research | Outperform |
| 2022-01-20 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-11-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 재개 | Wolfe Research | Outperform |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-30 | 개시 | Daiwa Securities | Outperform |
| 2020-11-30 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 개시 | Bernstein | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-07-31 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-09-03 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-08-01 | 다운그레이드 | Needham | Buy → Hold |
| 2019-05-23 | 재개 | Citigroup | Buy |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | In-line |
| 2019-03-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
버텍스 파마슈티컬 주식(VRTX)의 최신 뉴스
Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint - sharewise.com
Vertex’s new pain, blood disorder drugs miss Wall Street expectations - BioPharma Dive
Vertex shares slide on reliance on old product - The Pharma Letter
Why Vertex Skidded Despite Its Beat-And-Raise Quarter - Investor's Business Daily
Vertex Pharmaceuticals: Promising IgAN Market Position with Povetacicept’s Superior Efficacy and Patient-Friendly Administration - TipRanks
Analyst Barclays Maintains 'Equal-Weight' for VRTX, Raises PT to $414 | VRTX Stock News - GuruFocus
Vertex’s New Products Dim as Analysts Eye Kidney Portfolio - BioSpace
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $466 From $471, Maintains Market Perform Rating - MarketScreener
Barclays Adjusts Price Target on Vertex Pharmaceuticals to $414 From $408, Maintains Equalweight Rating - MarketScreener
VRTX: Stifel Lowers Price Target While Maintaining Hold Rating | - GuruFocus
VRTX Q3 Deep Dive: New Product Launches and Pipeline Progress Shape Outlook - TradingView
RBC Lowers Price Target on Vertex Pharmaceuticals to $415 From $423, Keeps Sector Perform Rating - MarketScreener
Is Vertex Pharmaceuticals Incorporated stock a safe investment in uncertain marketsWeekly Trade Analysis & Fast Exit and Entry Strategy Plans - newser.com
Can machine learning forecast Vertex Pharmaceuticals Incorporated recoveryJuly 2025 Institutional & Free Weekly Chart Analysis and Trade Guides - newser.com
Vertex Pharmaceuticals price target raised to $414 from $408 at Barclays - TipRanks
Bank of New York Mellon Corp Lowers Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Bank of Montreal Can Sells 50,652 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Outpaces Expectations With Fresh Growth - Finimize
Exit strategy if you’re trapped in Vertex Pharmaceuticals IncorporatedJobs Report & Free AI Powered Buy and Sell Recommendations - newser.com
Vertex Pharmaceuticals (VRTX) Reports Strong Q3 2025 Earnings with 11% Revenue Growth - GuruFocus
Vertex Pharmaceuticals Reports Strong Q3 2025 Results - TipRanks
Why Vertex Pharmaceuticals Incorporated (VX1) stock signals breakout potential - newser.com
Vertex Reports Third Quarter 2025 Financial Results - BioSpace
Vertex’s cystic fibrosis sales beat expectations, as newer drugs miss - The Boston Globe
Vertex Pharmaceuticals (VRTX) Beats Q3 Expectations, Shares Fall - GuruFocus
Vertex Pharmaceuticals (VRTX) Stock: Strong Q3 Results Drive 11% Revenue Growth - parameter.io
Earnings call transcript: Vertex Q3 2025 beats forecasts, stock gains - Investing.com
Vertex falls despite Q3 double beats as 2025 revenue guidance narrowed - Seeking Alpha
Vertex’s Cystic Fibrosis Sales Beat, as Newer Drugs Miss - Bloomberg.com
Vertex Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Vertex Pharmaceuticals (VRTX) Q3 Earnings Surpass Expectations - GuruFocus
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Vertex Pharmaceuticals Grows Past Cystic Fibrosis With New Hits - Finimize
Vertex beats quarterly estimates on cystic fibrosis demand, new drugs - MSN
Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs - MarketScreener
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations - Yahoo Finance
Vertex Pharma Dips Despite Quarterly Beat And Slight Guidance Book - MSN
After pain setback, Vertex spotlights renal portfolio in expectation-beating Q3 - FirstWord Pharma
Earnings Flash (VRTX) Vertex Pharmaceuticals Incorporated Posts Q3 Adjusted EPS $4.80 per Share, vs. FactSet Est of $4.58 - MarketScreener
Earnings Flash (VRTX) Vertex Pharmaceuticals Posts Q3 Adjusted EPS $4.80, vs. FactSet Est of $4.58 - MarketScreener
Vertex Beats Estimates on Strong Sales of Cystic Fibrosis Drugs - Bloomberg.com
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - Benzinga
Vertex Pharma’s Stock Has Tumbled. Earnings Will Stop the Pain. - MSN
Visual analytics tools that track Vertex Pharmaceuticals Incorporated performanceWeekly Trade Report & Smart Investment Allocation Tips - newser.com
Published on: 2025-11-03 07:39:53 - newser.com
Will Vertex Pharmaceuticals Incorporated benefit from macro trends2025 Analyst Calls & Growth Focused Entry Reports - newser.com
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Tredje AP fonden - MarketBeat
Telos Capital Management Inc. Increases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Torray Investment Partners LLC Grows Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Welch & Forbes LLC - MarketBeat
South Dakota Investment Council Sells 10,780 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
버텍스 파마슈티컬 (VRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.69%
1.56%
자본화:
|
볼륨(24시간):